| |
|
|
|
|
|||||||||
| |
|
|
|
|
|
|
|
|
|
||||
| |
|||||||||||||
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
About Sciele® Pharma, Inc. Sciele Pharma, Inc. is a pharmaceutical company
specializing in sales, marketing and development of branded prescription
products focused on Cardiovascular, Diabetes, Women's Health and
Pediatrics. The Company's Cardiovascular and Diabetes products treat
patients with high cholesterol, hypertension, high triglycerides,
unstable angina and Type 2 diabetes; its Women's Health products are
designed to improve the health and well-being of women and mothers and
their babies; and its Pediatrics products treat allergies, asthma,
coughs and colds, and attention deficit/hyperactivity disorder (ADHD).Founded in 1992 and headquartered in Atlanta, Georgia, Sciele Pharma employs more than 900 people. The Company's success is based on placing the needs of patients first, improving health and quality of life, and implementing its business platform - an Entrepreneurial Spirit, Innovation, Execution Excellence, Simplicity, and Teamwork. Solid Financial Results in the Third Quarter 2007
Sciele Pharma, Inc., a specialty
pharmaceutical company, reported increased revenues and earnings
for the third quarter and nine months ended September 30, 2007. Net
revenues for the third quarter of 2007 increased 33% to $99.4 million
from $74.8 million in the third quarter of 2006. Diluted earnings per
share (EPS) for the third quarter of 2007 increased 12% to $0.38
compared with $0.34 in the third quarter of 2006.
Earnings before interest, taxes, depreciation, amortization and stock compensation expense, EBITDAS, (a non-GAAP measure) were $32 million in the third quarter of 2007 compared with $26 million in the third quarter of 2006. Cash flow per share, also a non-GAAP measure, was $1.63 per share for the first nine months of 2007 compared with $1.27 in the prior year-period. Cardiovascular/Diabetes Products
Net revenues of the Company's Cardiovascular/Metabolic products, which include Sular, Triglide, Fortamet, Nitrolingual Pumpspray, and Altoprev, increased 10% to $65.4 million in the third quarter of 2007, compared with $59.6 million in the third quarter of 2006. The increase was primarily due to the continued growth of Sular and Nitrolingual Pumpspray as well as price increases implemented in the first quarter of 2007. Cardiovascular/Metabolic products represented 66% of the Company's total sales in the third quarter of 2007. Women's Health Products
Net revenues of the Company's Women's Health products, which include Prenate DHA, Prenate Elite, OptiNate, Zovirax, and Ponstel, increased 68% to $21.3 million in the third quarter of 2007 compared with $12.7 million in the third quarter of 2006. Women's Health products represented 21% of the Company's total sales in the third quarter of 2007. The Company's Prenate family of vitamins is a leading brand of prenatal vitamins in the United States. Pediatric and Other Products
Net revenues for the Company's Pediatric and other products, which include Orapred and Orapred ODT, Methylin Oral Solution and Methylin Chewable Tablets, Furadantin, Rondec and Rondec DM Syrups and Oral Drops; and Allegra Oral Suspension, increased to $12.7 million in the third quarter of 2007 compared with $2.4 million in the third quarter of 2006, primarily due to the acquisition of Alliant Pharmaceuticals. Sales of many of the products in this division are subject to seasonal sales fluctuations, with stronger sales in the first and fourth quarters of the year. Pediatric and other products represented 13% of the Company's total sales in the third quarter of 2007. Product Development
The Company's product pipeline includes nine products. One has recently been approved by the U.S. Food & Drug Administration (FDA), three are under review at the FDA and five are currently in pivotal Phase III trials. |
Legal Terms of Use • Privacy Policy
 |
Five Concourse Parkway Suite 1800 Atlanta, Georgia 30328 Phone: (800) 461-3696 |
©2006 Sciele Pharma,
Inc. GEN-WEB-02 Rev. 12/07 |